Menu

Epidermal Growth Factor (EGF)

Also known as: EGF, Human oligopeptide-1, Recombinant human epidermal growth factor, rhEGF

A signaling protein used in specialty skincare and post-procedure research, with delivery and product-specific evidence limits.

Risograph-style protein and skin-barrier delivery illustration
Editorial illustration

Epidermal growth factor is a signaling protein that binds the EGF receptor and influences cell growth and repair. Recombinant EGF appears in some cosmetic serums and post-procedure studies, but proteins are difficult to keep stable and deliver through intact skin. Small trials of specific formulas do not establish that every EGF cosmetic penetrates, reverses aging, or is appropriate after a procedure.3, 2

  • A protein signal, not a conventional exfoliating active1, 3
  • Stability and skin delivery are major formulation constraints1, 3
  • Evidence often involves procedures or delivery systems1, 3
  • Cancer-related concerns require careful context, not blanket claims1, 3

What is Epidermal Growth Factor (EGF)?

Native EGF is part of normal biology. Cosmetic products use recombinant or bioengineered growth-factor materials, whose sequence, vehicle, packaging, concentration, and stability determine whether a study applies.1, 3

Where it comes from

Natural sources

  • Produced naturally by human tissues and secretions

How it's made

Skincare EGF is generally produced by recombinant biotechnology rather than collected from human tissue.

What it does in products

  • Post-procedure support formula
  • Skin-conditioning signal protein
  • Photoaging marketing active

Benefits

Post-procedure recovery

limited evidence

Reviews find signals for improved healing measures after selected laser or resurfacing procedures.3

Protocols, delivery systems, and outcomes vary, and evidence does not support unsupervised use on every wound.

Acne lesion improvement

limited evidence

A small randomized study reported benefit with a specific topical EGF preparation.2

One study does not establish EGF as a standard acne therapy or isolate effects across commercial serums.

Evidence scope and limitations

Recombinant topical EGF in cosmetic and post-procedure skin use is covered; injectable products and medical wound devices are outside scope.

  • Studies use different delivery methods and formulas.
  • Long-term cosmetic safety and effectiveness data are limited.

Evidence last checked: 2026-09-28

Side effects & safety

Redness, stinging, or rash (uncommon)Post-procedure skin may react to the vehicle or other ingredients.

Safety considerations

  • Use around procedures or on compromised skin only with clinician guidance during pregnancy.
  • Procedure aftercare protocols
  • Other irritating actives on recently treated skin
  • Not for: Applying a cosmetic serum to an open or infected wound without medical direction
  • Not for: Known allergy to the formula
3, 4

Amounts studied & product use

These figures describe research or common product use, not a personal dose or treatment recommendation.

In skincare studies and products

There is no interchangeable consumer percentage. Follow the tested product protocol or the treating clinician's post-procedure directions.

3

Regulatory status

  • Cosmetic EGF serums are not FDA-approved drugs for wound healing, acne, or skin rejuvenation.
  • INCI name on cosmetic labels: Human Oligopeptide-1 may appear on some labels; nomenclature and material specifications vary..
4

The label does not prove delivery

EGF is large, structurally fragile, and sensitive to its vehicle. A formula used with microneedling or laser-created channels answers a different question from a serum applied to intact skin.

3, 1

Frequently asked questions

Does EGF penetrate intact skin?

Delivery is a central limitation; penetration cannot be assumed from the ingredient list.3, 2

Can I use EGF after microneedling?

Only use a product and schedule approved by the clinician performing the procedure.3, 2

The bottom line

EGF is biologically active, but cosmetic effectiveness depends on identity, stability, delivery, and the exact clinical context—not the growth-factor label alone.

References

  1. Epidermal growth factor: compound summary. PubChem, National Library of Medicine (2026) · ingredient monograph · CID 56841751
  2. Topical epidermal growth factor for the improvement of acne lesions: a randomized, double-blinded, placebo-controlled, split-face trial. International Journal of Dermatology (2014) · randomized trial · PMID 24962549
  3. Review of post-laser-resurfacing topical agents for improved healing and cosmesis. The Journal of Clinical and Aesthetic Dermatology (2021) · other · PMID 34840654
  4. FDA Authority Over Cosmetics: How Cosmetics Are Not FDA-Approved, but Are FDA-Regulated. U.S. Food and Drug Administration (2013) · government guidance

Revision history

  1. Initial publication with claim-level citations, formulation limits, safety context, and editorial evidence review.